Clinical risk stratification models for smoldering multiple myeloma
| Characteristic . | PETHEMA model13 . | Mayo Clinic 2018 model14 . | IMWG 2020 model8 . | |||
|---|---|---|---|---|---|---|
| Risk factors (points) | Immunoparesis Aberrant plasma cells/BMPC ≥95% | 1 1 | M-protein >2 FLC ratio >20 BMPC >20% | 1 1 1 | FLC ratio 0-10 10-25 25-40 >40 M-protein 0-1.5 1.5-3 >3 BMPC % 0-15 >15-20 >20-30 >30-40 >40 FISH abnormality | 0 2 3 5 0 3 4 0 2 3 5 6 2 |
| Level of risk (score) | Low Intermediate High | 0 1 2 | Low Intermediate High | 0 1 ≥2 | Low Low-intermediate Intermediate High | 0-4 5-8 9-12 >12 |
| Risk of progression at 2 years (%)* | Low Intermediate High | 5 35 50 | Low Intermediate High | 10 26 47 | Low Low-intermediate Intermediate High | 4 26 51 73 |
| Characteristic . | PETHEMA model13 . | Mayo Clinic 2018 model14 . | IMWG 2020 model8 . | |||
|---|---|---|---|---|---|---|
| Risk factors (points) | Immunoparesis Aberrant plasma cells/BMPC ≥95% | 1 1 | M-protein >2 FLC ratio >20 BMPC >20% | 1 1 1 | FLC ratio 0-10 10-25 25-40 >40 M-protein 0-1.5 1.5-3 >3 BMPC % 0-15 >15-20 >20-30 >30-40 >40 FISH abnormality | 0 2 3 5 0 3 4 0 2 3 5 6 2 |
| Level of risk (score) | Low Intermediate High | 0 1 2 | Low Intermediate High | 0 1 ≥2 | Low Low-intermediate Intermediate High | 0-4 5-8 9-12 >12 |
| Risk of progression at 2 years (%)* | Low Intermediate High | 5 35 50 | Low Intermediate High | 10 26 47 | Low Low-intermediate Intermediate High | 4 26 51 73 |
Estimated from Figure 4B in the original publication for the PETHEMA risk model.